Hoth Therapeutics, Inc. (HOTH): Nasdaq/NYSE listing notice — Hoth Therapeutics receives Nasdaq delisting notice for bid price below $1.00

Hoth Therapeutics, Inc.

Closing bid price of common stock below $1.00 for 30 consecutive business days ending May 12, 2025.
Company has 180 days, until November 10, 2025, to regain compliance with minimum bid price rule.
To cure, stock must close at or above $1.00 for at least 10 consecutive business days.
Company may consider a reverse stock split among available options to regain compliance.
Nasdaq notice has no immediate effect on trading; stock continues on Nasdaq Capital Market under HOTH.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Hoth Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2), 5810(c)(3)(A)

Exact text from the filing

May 13, 2025, Hoth Therapeutics, Inc. (the “Company”) was notified (the “Notification Letter”) by The Nasdaq Stock Market, LLC (“Nasdaq”) that it is not in compliance with the minimum bid price requirements set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. Ba

View on SEC.gov

Browse all listing & compliance notices →

Hoth Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-25-044894

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.